| Literature DB >> 34516621 |
Ozan M Demir1, Haseeb Rahman1, Tim P van de Hoef2, Javier Escaned3, Jan J Piek2, Sven Plein4, Divaka Perera1.
Abstract
Intracoronary physiology testing has emerged as a valuable diagnostic approach in the management of patients with chronic coronary syndrome, circumventing limitations like inferring coronary function from anatomical assessment and low spatial resolution associated with angiography or non-invasive tests. The value of hyperaemic translesional pressure ratios to estimate the functional relevance of coronary stenoses is supported by a wealth of prognostic data. The continuing drive to further simplify this approach led to the development of non-hyperaemic pressure-based indices. Recent attention has focussed on estimating physiology without even measuring coronary pressure. However, the reduction in procedural time and ease of accessibility afforded by these simplifications needs to be counterbalanced against the increasing burden of physiological assumptions, which may impact on the ability to reliably identify an ischaemic substrate, the ultimate goal during catheter laboratory assessment. In that regard, measurement of both coronary pressure and flow enables comprehensive physiological evaluation of both epicardial and microcirculatory components of the vasculature, although widespread adoption has been hampered by perceived technical complexity and, in general, an underappreciation of the role of the microvasculature. In parallel, entirely non-invasive tools have matured, with the utilization of various techniques including computational fluid dynamic and quantitative perfusion analysis. This review article appraises the strengths and limitations for each test in investigating myocardial ischaemia and discusses a comprehensive algorithm that could be used to obtain a diagnosis in all patients with angina scheduled for coronary angiography, including those who are not found to have obstructive epicardial coronary disease.Entities:
Keywords: Coronary circulation; Coronary physiology; Stable coronary artery disease
Mesh:
Year: 2022 PMID: 34516621 PMCID: PMC8757583 DOI: 10.1093/eurheartj/ehab548
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Graphical AbstractIllustration of hierarchy of coronary indices and optimal coronary indices by coronary artery disease substrate. CFR, coronary flow reserve; CT, computed tomography; FFR, fractional flow reserve; hMR, hyperaemic microvascular resistance; hSR, hyperaemic stenosis resistance; iFR, instantaneous wave-free ratio; IMR, index of microvascular resistance; NHPR, non-hyperaemic pressure ratio; Pd/Pa, resting distal to aortic pressure ratio; QFR, quantitative flow reserve.
Coronary physiology indices
| Index | Measures | Modality | Threshold | Notes |
|---|---|---|---|---|
| FFR | Epicardial stenosis severity | Pressure | ≤0.80 |
Validated in large population Class I indication in ESC and ACC/AHA guideline Cost effective |
| NHPR | Epicardial stenosis severity | Pressure | ≤0.89 |
Does not require pharmacological hyperaemia iFR—Class I indication in ESC and ACC/AHA guideline |
| hSR | Epicardial stenosis severity | Pressure and Doppler | ≥0.80 Hg/cm s |
Low variability Stenosis specific in presence of serial or complex coronary artery disease, and left ventricular dysfunction |
| CFR | Epicardial stenosis severity and microvascular resistance | Doppler/thermodilution and pressure |
<2.5 |
In isolation does not distinguish between epicardial and microvascular compartments |
| hMR | Microvascular resistance | Doppler | >2.5 |
Pressure and flow velocity based Independent of stenosis severity |
| IMR | Microvascular resistance | Pressure and thermodilution | ≥25 |
Pressure and thermodilution derived flow based Independent of stenosis severity Validated in CCS and ACS |
ACC/AHA, American College of Cardiology/American Heart Association; ACS, actue coronary syndrome CCS, chronic coronary syndrome; CFR, coronary flow reserve; FFR, fractional flow reserve; hMR, hyperaemic microvascular resistance; hSR, hyperaemic stenosis resistance; IMR, index of microvascular resistance; iFR, instantaneous flow reserve; NHPR, non-hyperaemic pressure ratio.
Coronary vasoactive drugs
| Drug | Dose | Hyperaemia | Half life | Side effects | Advantage/disadvantages |
|---|---|---|---|---|---|
| IV adenosine | 140 μg/kg/min | 1–2 min | 1–10 s |
AV block Chest tightness Bronchospasm |
Steady state hyperaemia Can be used for ostial lesions Pullback assessment of serial and diffuse disease- May be poorly tolerated by some patients Time taken for repeat measurements |
| IC adenosine | 36–120 μg LCA 18–60 μg RCA | 3–8 s | 1–10 s |
AV block |
Well tolerated Quick repeat measurements Unable to do pullback Unable to interrogate ostial lesions |
| IC papaverine | 10 mg LCA 15 mg RCA | 30–60 s | 2 min |
QT prolongation Ventricular tachycardia Long half-life Lower blood pressure |
Can be used in patients with asthma and COPD Safety profile not as favourable as adenosine |
AV, atrioventricular; COPD, chronic obstructive pulmonary disease; IC, intracoronary; IV, intravenous; LCA, left coronary artery; RCA, right coronary artery.